FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least 2 oral antidepressants, according to a news release issued by Johnson & Johnson.
Revolutionary nasal spray offers hope by potentially delaying Alzheimer's progression through cutting-edge neurological ...
The results? A nasal spray of oxytocin significantly reduced acute feelings of loneliness in participants, especially during group therapy sessions, even months after treatment. In the study ...
Nasal sprays can be an effective medication option to manage migraine symptoms. Often, nasal sprays can provide faster relief than oral medication. You may have heard of nasal sprays as a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback